Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex

Jana Marx, René Welte, Tiziana Gasperetti, Patrizia Moser, Ronny Beer, Martin Ortler, Martina Jeske, Ramona Stern, Andreas Pomaroli, Michael Joannidis, Romuald Bellmann
Jana Marx
aClinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
René Welte
aClinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiziana Gasperetti
aClinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Moser
bDepartment of Pathology, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronny Beer
cNeurological ICU, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Ortler
dNeurosurgical ICU, Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Jeske
eHospital Pharmacy, Innsbruck General Hospital, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramona Stern
eHospital Pharmacy, Innsbruck General Hospital, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Pomaroli
fTransplant ICU, Department of Anesthesia and Critical Care, Centre of Operative Medicine, Innsbruck General Hospital and Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Joannidis
gDivision of Intensive Care and Emergency Medicine, Department Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romuald Bellmann
aClinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00275-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Anidulafungin and micafungin were quantified in cerebrospinal fluid (CSF) of critically ill adults and in cerebral cortex of deceased patients. In CSF, anidulafungin levels (<0.01 to 0.66 μg/ml) and micafungin levels (<0.01 to 0.16 μg/ml) were lower than those in plasma concentrations (0.77 to 5.07 and 1.21 to 8.70 μg/ml, respectively) drawn simultaneously. In cerebral cortex, anidulafungin and micafungin levels were 0.21 to 2.34 and 0.18 to 2.88 μg/g, respectively. Thus, MIC values of several pathogenic Candida strains exceed concentrations in CSF and in brain.

TEXT

The echinocandins anidulafungin and micafungin are recommended for treatment of invasive candidiasis (1, 2). Candidiasis of the central nervous system (CNS) is associated with a high mortality of 80% to 100% in immunocompromised patients (3, 4). Because knowledge on penetration of echinocandins into human CNS is limited, we quantified anidulafungin and micafungin in the cerebrospinal fluid (CSF) of critically ill patients and the cerebral cortex of deceased patients.

The study was approved by the local ethics committee and performed in accordance with the Declaration of Helsinki and Austrian law. Written informed consent for scientific use of CSF and blood samples was granted by competent patients. Post hoc consent was obtained from patients who were incompetent at the time of enrollment. Autopsy samples were taken from deceased patients who, on admission, had permitted scientific use of residual specimens taken for clinical laboratory tests.

CSF was taken during diagnostic lumbar puncture (LP) or via external ventricular drain (EVD) from critically ill adults treated with anidulafungin or micafungin. Simultaneously, we took 2-ml arterial blood samples. CSF and plasma were stored at –80°C.

Anidulafungin and micafungin concentrations were quantified by high-performance liquid chromatography and UV detection (HPLC-UV) as described previously (5). Noncompartmental pharmacokinetics was calculated with Kinetica 2000 (InnaPhase Corporation, Champs-sur-Marne, France). The area under the concentration-time curve from 0 to 24 h (AUC0–24) was computed with the log-linear method when the concentration in a trapezoid decreased or with the trapezoidal method when the concentration increased.

The cerebral cortex of deceased patients who had received anidulafungin or micafungin within their last 30 days of life was sampled during autopsy, which is routinely performed for quality assurance in Austrian hospitals. Anidulafungin and micafungin were extracted from 0.2 g of tissue by addition of 250 μl of acetonitrile and 250 μl of methanol (Sigma-Aldrich, Vienna, Austria), homogenization with a Precellys homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France) at 4,500 rpm (twice for 25 s, 2-s break), and centrifugation for 5 min at 8°C and 4,665 × g. For calibration, we used porcine brain samples spiked with anidulafungin or micafungin and homogenized and proceeded in the same manner. Both echinocandins were quantified by HPLC-UV at 306 nm (5). The lower limit of quantification was 0.05 μg/g for anidulafungin and 0.10 μg/g for micafungin. The extraction recovery from brain was ∼40% and ∼60% for anidulafungin and micafungin, respectively.

The significance of the difference between CSF and plasma concentrations was assessed by Wilcoxon matched-pairs test, and the difference between the penetration ratio (PR) of anidulafungin and PR of micafungin was calculated by Mann-Whitney U test using IBM SPSS statistics 24.0. PR was the ratio between the AUC0–24 in CSF and that in plasma over 24 h (AUC0–24 CSF/AUC0–24 plasma), when multiple samples were drawn via EVD. For single samples drawn by LP, PR was the ratio between the concentration in CSF and that in plasma (CCSF/Cplasma).

CSF samples were obtained from three patients on anidulafungin and three patients on micafungin. One patient on anidulafungin (patient 2) and one patient on micafungin (patient 5) had undergone EVD (Table 1; Fig. 1). CSF concentrations of anidulafungin (<0.7 μg/ml) and micafungin (<0.2 μg/ml) were lower than the corresponding plasma concentrations (P < 0.05 and P < 0.01, respectively) (Table 1; Fig. 1). PRs of anidulafungin and micafungin were similar (P = 0.40). In the cerebral cortex of four deceased patients, anidulafungin had reached concentrations of 0.21 to 2.34 μg/g. Brain concentrations of micafungin were <0.10 to 2.88 μg/g (n = 6). Anidulafungin and micafungin were measurable even 13 and 10 days, respectively, after treatment (Table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Penetration of anidulafungin or micafungin into cerebrospinal fluid of critically ill patients

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Concentration-time profiles of anidulafungin (AFG) and micafungin (MFG) in cerebrospinal fluid (CSF) and plasma over the dosage interval of 24 h.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Anidulafungin and micafungin concentrations in autopsy samples of cerebral cortex

In some of the CSF and brain specimens, measured anidulafungin and micafungin concentrations were below the MICs reported for relevant Candida species (i.e., 0.008 to 4.0 μg/ml) (6). In the CSF of patients 2 and 5, the target AUC0–24/MIC ratios of 2,782 and 5,299 suggested for anidulafungin and micafungin, respectively, have not been achieved, not even for highly susceptible Candida strains (6, 7). However, the relevance of in vitro MIC values for antifungal activity of echinocandins in CSF and in CNS remains to be clarified. In CSF, protein binding of anidulafungin and micafungin is unknown. In vitro, protein binding obviously affects MICs (8, 9). We did not separate protein-bound from free echinocandins. In our small and heterogeneous study population, only two patients (patients 3 and 6) reached steady state, when CSF was taken by LP, and only two patients (patients 2 and 4) suffered from CNS infections that might have enhanced permeability of the blood-brain barrier (10). However, CSF concentrations and PRs of anidulafungin and micafungin in patients 2 and 4 were similar to those in our other patients.

During cerebral aspergillosis, the 2-fold maximum dose of micafungin (i.e., 300 mg/day) achieved CSF concentrations of <0.02 μg/ml (11). After intracranial hemorrhage, micafungin CSF levels amounted to 0.019 to 4.66 μg/ml (12). Caspofungin was undetectable in CSF during meningeal coccidioidomycosis and in 9 of 11 CSF samples from children with hematological malignancies (13, 14). In infants with meningitis, daily high doses of 8 to 10 mg/kg of micafungin resulted in CSF concentrations of 0.80 to 1.80 μg/ml (15). In neonatal rats, anidulafungin brain concentrations of 1.60 and 4.40 μg/g were measured (16). Along with the higher dosage, the immaturity of the blood-brain barrier might explain the higher penetration into CSF and brain.

In brain specimens, we cannot rule out minor agonal or postmortem changes of anidulafungin and micafungin concentrations, although anidulafungin and micafungin were stable in the brains of deceased patients for at least 96 h. Brain specimens consist of various compartments, e.g., different cells, extracellular matrix, and blood vessels. Anidulafungin and micafungin were not quantified on a cellular level or in different brain areas. Echinocandin extraction from human brain might yield slightly lower recovery than extraction from external standards. In rats, [3H]caspofungin brain concentrations were ≤0.16 μg eq/g (17). In rabbits, micafungin brain concentrations were <0.19 μg/g, and those of anidulafungin were <4.0 μg/g (18, 19). In a biopsy sample of a brain abscess, a micafungin concentration of 0.26 μg/g was measured (20).

In conclusion, anidulafungin and micafungin concentrations in CSF and in brain specimens were below the in vitro MIC values of several pathogenic Candida strains. Studies on target-site pharmacodynamics are required for assessment of antifungal efficacy.

(Parts of the data were presented at the 23rd and 25th Scientific Symposium of the Austrian Pharmacological Society, 2017 and 2019, Innsbruck, Austria.)

ACKNOWLEDGMENTS

This study was supported by the Austrian Science Fund (FWF) (grant KLI 565-B31).

We thank Thomas Nachtigall, Obersöchering, Germany, for donation of the HPLC system and for technical support. Porcine brain was kindly provided by Landmetzgerei Piegger, Sistrans, Austria.

R.B. has received an IIR grant from Pfizer; research support from Rokitan, Vienna, Austria; and a lecture fee from Basilea Pharmaceutica, Basel, Switzerland. He is a member of an advisory board of Merck Sharp & Dohme.

Otherwise, we have no conflicts of interest to declare.

FOOTNOTES

    • Received 11 February 2020.
    • Returned for modification 20 February 2020.
    • Accepted 17 April 2020.
    • Accepted manuscript posted online 27 April 2020.
  • Copyright © 2020 Marx et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes DR,
    4. Clancy CJ,
    5. Marr KA,
    6. Ostrosky-Zeichner L,
    7. Reboli AC,
    8. Schuster MG,
    9. Vazquez JA,
    10. Walsh TJ,
    11. Zaoutis TE,
    12. Sobel JD
    . 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50. doi:10.1093/cid/civ933.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cornely OA,
    2. Bassetti M,
    3. Calandra T,
    4. Garbino J,
    5. Kullberg BJ,
    6. Lortholary O,
    7. Meersseman W,
    8. Akova M,
    9. Arendrup MC,
    10. Arikan-Akdagli S,
    11. Bille J,
    12. Castagnola E,
    13. Cuenca-Estrella M,
    14. Donnelly JP,
    15. Groll AH,
    16. Herbrecht R,
    17. Hope WW,
    18. Jensen HE,
    19. Lass-Flörl C,
    20. Petrikkos G,
    21. Richardson MD,
    22. Roilides E,
    23. Verweij PE,
    24. Viscoli C,
    25. Ullmann AJ, ESCMID Fungal Infection Study Group
    . 2012. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37. doi:10.1111/1469-0691.12039.
    OpenUrlCrossRef
  3. 3.↵
    1. Góralska K,
    2. Blaszkowska J,
    3. Dzikowiec M
    . 2018. Neuroinfections caused by fungi. Infection 46:443–459. doi:10.1007/s15010-018-1152-2.
    OpenUrlCrossRef
  4. 4.↵
    1. Schwartz S,
    2. Kontoyiannis DP,
    3. Harrison T,
    4. Ruhnke M
    . 2018. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol 17:362–372. doi:10.1016/S1474-4422(18)30030-9.
    OpenUrlCrossRef
  5. 5.↵
    1. Welte R,
    2. Oberacher H,
    3. Schwärzler B,
    4. Joannidis M,
    5. Bellmann R
    . 2020. Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci 1139:121937. doi:10.1016/j.jchromb.2019.121937.
    OpenUrlCrossRef
  6. 6.↵
    1. Pfaller MA,
    2. Messer SA,
    3. Rhomberg PR,
    4. Castanheira M
    . 2017. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. Int J Antimicrob Agents 50:352–358. doi:10.1016/j.ijantimicag.2017.03.028.
    OpenUrlCrossRef
  7. 7.↵
    1. Andes D,
    2. Diekema DJ,
    3. Pfaller MA,
    4. Bohrmuller J,
    5. Marchillo K,
    6. Lepak A
    . 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54:2497–2506. doi:10.1128/AAC.01584-09.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ernst EJ,
    2. Roling EE,
    3. Petzold CR,
    4. Keele DJ,
    5. Klepser ME
    . 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46:3846–3853. doi:10.1128/aac.46.12.3846-3853.2002.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Odabasi Z,
    2. Paetznick V,
    3. Rex JH,
    4. Ostrosky-Zeichner L
    . 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51:4214–4216. doi:10.1128/AAC.01589-06.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Nau R,
    2. Sörgel F,
    3. Eiffert H
    . 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23:858–883. doi:10.1128/CMR.00007-10.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Okugawa S,
    2. Ota Y,
    3. Tatsuno K,
    4. Tsukada K,
    5. Kishino S,
    6. Koike K
    . 2007. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 39:344–346. doi:10.1080/00365540600951333.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Yamada N,
    2. Kumada K,
    3. Kishino S,
    4. Mochizuki N,
    5. Ohno K,
    6. Ogura S
    . 2011. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother 17:731–734. doi:10.1007/s10156-011-0240-3.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Hsue G,
    2. Napier JT,
    3. Prince RA,
    4. Chi J,
    5. Hospenthal DR
    . 2004. Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 54:292–294. doi:10.1093/jac/dkh306.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Strenger V,
    2. Farowski F,
    3. Müller C,
    4. Hofer N,
    5. Dornbusch HJ,
    6. Sperl D,
    7. Lackner H,
    8. Benesch M,
    9. Urban C
    . 2017. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses. Int J Antimicrob Agents 50:272–275. doi:10.1016/j.ijantimicag.2017.02.024.
    OpenUrlCrossRef
  15. 15.↵
    1. Auriti C,
    2. Falcone M,
    3. Ronchetti MP,
    4. Goffredo BM,
    5. Cairoli S,
    6. Crisafulli R,
    7. Piersigilli F,
    8. Corsetti T,
    9. Dotta A,
    10. Pai MP
    . 2016. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Chemother 60:7333–7339. doi:10.1128/AAC.01172-16.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ripp SL,
    2. Aram JA,
    3. Bowman CJ,
    4. Chmielewski G,
    5. Conte U,
    6. Cross DM,
    7. Gao H,
    8. Lewis EM,
    9. Lin J,
    10. Liu P,
    11. Schlamm HT
    . 2012. Tissue distribution of anidulafungin in neonatal rats. Birth Defects Res B Dev Reprod Toxicol 95:89–94. doi:10.1002/bdrb.20347.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Stone JA,
    2. Xu X,
    3. Winchell GA,
    4. Deutsch PJ,
    5. Pearson PG,
    6. Migoya EM,
    7. Mistry GC,
    8. Xi L,
    9. Miller A,
    10. Sandhu P,
    11. Singh R,
    12. deLuna F,
    13. Dilzer SC,
    14. Lasseter KC
    . 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 48:815–823. doi:10.1128/aac.48.3.815-823.2004.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Groll AH,
    2. Mickiene D,
    3. Petraitis V,
    4. Petraitiene R,
    5. Ibrahim KH,
    6. Piscitelli SC,
    7. Bekersky I,
    8. Walsh TJ
    . 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 45:3322–3327. doi:10.1128/AAC.45.12.3322-3327.2001.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Groll AH,
    2. Mickiene D,
    3. Petraitiene R,
    4. Petraitis V,
    5. Lyman CA,
    6. Bacher JS,
    7. Piscitelli SC,
    8. Walsh TJ
    . 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 45:2845–2855. doi:10.1128/AAC.45.10.2845-2855.2001.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Lat A,
    2. Thompson GR,
    3. Rinaldi MG,
    4. Dorsey SA,
    5. Pennick G,
    6. Lewis JS
    . 2010. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob Agents Chemother 54:943–944. doi:10.1128/AAC.01294-09.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
Jana Marx, René Welte, Tiziana Gasperetti, Patrizia Moser, Ronny Beer, Martin Ortler, Martina Jeske, Ramona Stern, Andreas Pomaroli, Michael Joannidis, Romuald Bellmann
Antimicrobial Agents and Chemotherapy Jun 2020, 64 (7) e00275-20; DOI: 10.1128/AAC.00275-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
Jana Marx, René Welte, Tiziana Gasperetti, Patrizia Moser, Ronny Beer, Martin Ortler, Martina Jeske, Ramona Stern, Andreas Pomaroli, Michael Joannidis, Romuald Bellmann
Antimicrobial Agents and Chemotherapy Jun 2020, 64 (7) e00275-20; DOI: 10.1128/AAC.00275-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

echinocandins
antifungal target-site pharmacokinetics
CNS penetration
fungal meningoencephalitis
CNS candidiasis
critically ill

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596